Thomas Tursz logo  logo

Thomas Tursz

Chairman, Research Steering Committee, ARC Foundation (France)


Professor Thomas Tursz was born in Krakow, Poland in 1946
MD 1972 – PhD 1977
Full Professor of Oncology at the Faculty of Medicine Paris-Sud (1986)
Professor ‘de classe exceptionnelle’ since 2005
He is:
- Honorary General Director of the Institut Gustave-Roussy (IGR), since October 1st 2010
- Professor Emeritus of Oncology- University of Paris-Sud/Paris XI since September 1st, 2011
He has been:
- General Director of the Institut Gustave-Roussy (IGR), 1994-2010
- Director of the Doctoral School of Oncology: “Biology – Medicine – Health”(2000-2010)
- President of the French Federation of Comprehensive Anticancer Centres (FNCLCC),(2004-2010) (now known as UNICANCER)
- Chairman of the Scientific Advisory Committee (SAC) of the EORTC (2003-2006)
- Vice-President of the EORTC Board (2006-2009)
- President (Chairman) of the OECI (Organisation of the European Cancer Institutes (2002-2005), gathering more than 65 European Cancer
Centers in 30 countries. Under his chairmanship, has been launched the “Comprehensive Cancer Center Accreditation Process”. 40 European
Centers have now been accredited by the OECI
- Member of the Scientific Steering committee of the EUROCAN Platform, network of excellence gathering 17 major European Comprehensive
Cancer Centers, supported by the European Union (2008-2013)
He still is:
- Elected Member of the European Academy of Cancer Sciences (since 2009)
- Regular expert for Cancer Projects for the Framework Research Programs of the European Union
- Member of several Scientific Advisory Committees of several major Cancer Centers (Cancer Center Karolinska, Stockholm, Sweden, Institut Jules
Bordet, Brussels, Belgium, Istituto Nazionale dei Tumori, Milan, Italy, European Institute of Oncology, Milan, Italy, Cancer Center Dresden,
Germany, Institut Curie, Paris, France, Centre Léon-Bérard, Lyon,France)
- Co-Founder with Dr. John Mendelsohn of the WIN Consortium on Personalized Medicine and first Vice-President of WIN (2010-2012)
- Chairman of the International Evaluation Committee of the DKTK (German national network for cancer translational research, gathering eight
major centers, coordinated by DKFZ-Heidelberg), supported by BFMF (German ministry of researcher and higher education)since 2016
- Chairman of the International Scientific Strategy Committee of the ARC (Association pour la Recherche sur le Cancer) Foundation, Paris,
France(since 2014).

Thomas Tursz is both a medical oncologist and a researcher.
He was the Director of the CNRS** Biology of Tumours Laboratory (URA CNRS 1156)at the IGR from 1984 to 1996 and Head of the Department of Medicine from 1992-1994. He was President of the International Association for Research on the Epstein-Barr Virus and Associated Diseases from 1994 to 1996.

From the clinical point of view, his Department has conducted several important trials in breast, lung cancer and soft tissue sarcomas and was a
pioneer in France of cytokines and gene therapy in human clinical trials.

- Former Secretary of the Soft Tissue and Bone Sarcoma Group of the EORTC,he was Chairman of this Group from 1993 to 1996. In 1994, the first trial on gene therapy in lung cancer using a recombinant adenovirus was initiated in his department at the Institut Gustave Roussy.

Under his Directorship, the Institut Gustave Roussy (IGR) has became an European leader in the field of the molecular and genetic classification of
human tumours, and is now one of the very first institutes for early clinical trials for innovative targeted agents, and a world leader in the innovative area of personalized treatments of cancers.

His work has been awarded with several prestigious scientific prizes such as the Oncology Award “Prix de Cancérologie” from the French National League Against Cancer in 1979, the Bernard-Halpern Immunology Award in 1983,the Rosen Oncology Award from the Medical Research Foundation in 1989
and the Grand Prix in Oncology from the Academy of Medicine in 1992, the Hamilton Fairley Award for Clinical Research from the European Society of
Medical Oncology (ESMO) in 1998 and the Prix de Rayonnement Français in 2001.

He is the author of 350 international papers in peer-reviewed journals including Science, Nature, PNAS, JNCI, JCO, J. Biol. Chem., EMBO J., Lancet,
Lancet Oncology, British Medical Journal.

Thomas Tursz logo

Thomas Tursz

Chairman, Research Steering Committee, ARC Foundation (France)


 logo

Professor Thomas Tursz was born in Krakow, Poland in 1946
MD 1972 – PhD 1977
Full Professor of Oncology at the Faculty of Medicine Paris-Sud (1986)
Professor ‘de classe exceptionnelle’ since 2005
He is:
- Honorary General Director of the Institut Gustave-Roussy (IGR), since October 1st 2010
- Professor Emeritus of Oncology- University of Paris-Sud/Paris XI since September 1st, 2011
He has been:
- General Director of the Institut Gustave-Roussy (IGR), 1994-2010
- Director of the Doctoral School of Oncology: “Biology – Medicine – Health”(2000-2010)
- President of the French Federation of Comprehensive Anticancer Centres (FNCLCC),(2004-2010) (now known as UNICANCER)
- Chairman of the Scientific Advisory Committee (SAC) of the EORTC (2003-2006)
- Vice-President of the EORTC Board (2006-2009)
- President (Chairman) of the OECI (Organisation of the European Cancer Institutes (2002-2005), gathering more than 65 European Cancer
Centers in 30 countries. Under his chairmanship, has been launched the “Comprehensive Cancer Center Accreditation Process”. 40 European
Centers have now been accredited by the OECI
- Member of the Scientific Steering committee of the EUROCAN Platform, network of excellence gathering 17 major European Comprehensive
Cancer Centers, supported by the European Union (2008-2013)
He still is:
- Elected Member of the European Academy of Cancer Sciences (since 2009)
- Regular expert for Cancer Projects for the Framework Research Programs of the European Union
- Member of several Scientific Advisory Committees of several major Cancer Centers (Cancer Center Karolinska, Stockholm, Sweden, Institut Jules
Bordet, Brussels, Belgium, Istituto Nazionale dei Tumori, Milan, Italy, European Institute of Oncology, Milan, Italy, Cancer Center Dresden,
Germany, Institut Curie, Paris, France, Centre Léon-Bérard, Lyon,France)
- Co-Founder with Dr. John Mendelsohn of the WIN Consortium on Personalized Medicine and first Vice-President of WIN (2010-2012)
- Chairman of the International Evaluation Committee of the DKTK (German national network for cancer translational research, gathering eight
major centers, coordinated by DKFZ-Heidelberg), supported by BFMF (German ministry of researcher and higher education)since 2016
- Chairman of the International Scientific Strategy Committee of the ARC (Association pour la Recherche sur le Cancer) Foundation, Paris,
France(since 2014).

Thomas Tursz is both a medical oncologist and a researcher.
He was the Director of the CNRS** Biology of Tumours Laboratory (URA CNRS 1156)at the IGR from 1984 to 1996 and Head of the Department of Medicine from 1992-1994. He was President of the International Association for Research on the Epstein-Barr Virus and Associated Diseases from 1994 to 1996.

From the clinical point of view, his Department has conducted several important trials in breast, lung cancer and soft tissue sarcomas and was a
pioneer in France of cytokines and gene therapy in human clinical trials.

- Former Secretary of the Soft Tissue and Bone Sarcoma Group of the EORTC,he was Chairman of this Group from 1993 to 1996. In 1994, the first trial on gene therapy in lung cancer using a recombinant adenovirus was initiated in his department at the Institut Gustave Roussy.

Under his Directorship, the Institut Gustave Roussy (IGR) has became an European leader in the field of the molecular and genetic classification of
human tumours, and is now one of the very first institutes for early clinical trials for innovative targeted agents, and a world leader in the innovative area of personalized treatments of cancers.

His work has been awarded with several prestigious scientific prizes such as the Oncology Award “Prix de Cancérologie” from the French National League Against Cancer in 1979, the Bernard-Halpern Immunology Award in 1983,the Rosen Oncology Award from the Medical Research Foundation in 1989
and the Grand Prix in Oncology from the Academy of Medicine in 1992, the Hamilton Fairley Award for Clinical Research from the European Society of
Medical Oncology (ESMO) in 1998 and the Prix de Rayonnement Français in 2001.

He is the author of 350 international papers in peer-reviewed journals including Science, Nature, PNAS, JNCI, JCO, J. Biol. Chem., EMBO J., Lancet,
Lancet Oncology, British Medical Journal.


Why WIN